コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 DHEA accelerated impaired healing in an impaired healing
2 DHEA action involves induction of PPARalpha mRNA and pro
3 DHEA also increased miR-21 in primary human hepatocytes
4 DHEA and androstenedione are synthesized by the adrenals
5 DHEA and testosterone appear to interact and modulate th
6 DHEA did not alter the small number (<3%) of newly forme
7 DHEA directly inhibited human and murine Th17 cells, ind
8 DHEA dosing was flexible (100-400 mg/day).
9 DHEA increased androgen receptor, c-Fos, and c-Jun recru
10 DHEA increased c-Jun, but not c-Fos, protein expression
11 DHEA increased ERK1/2 and c-Src phosphorylation in a GPE
12 DHEA induced both PPARalpha mRNA and protein levels, as
13 DHEA is widely available as a dietary supplement without
14 DHEA levels were associated with increases in cortical t
15 DHEA promoted nuclear exclusion of FoxO1 that was blocke
16 DHEA reduced memory accuracy for emotional stimuli, and
17 DHEA regulates microglial inflammatory responses through
18 DHEA replacement could play a role in prevention and tre
19 DHEA showed no evidence of efficacy in SS.
20 DHEA stimulates axonal growth from specific populations
21 DHEA supplementation in older women, but not in men, imp
22 DHEA treatment of endothelial cells increased PKA activi
23 DHEA was previously shown to bind to the nerve growth fa
24 DHEA, like G-1, increased GPER and ERalpha36 mRNA and pr
25 DHEA-stimulated phosphorylation of FoxO1 was inhibited b
26 DHEA-sulfate (DHEA-S), DHEA, and 17beta-estradiol stimul
28 campal tissue (percentage conversion of [14C]DHEA to [14C]7alpha-hydroxyDHEA) was decreased selective
30 as higher in women with INSR mutations after DHEA than in women with PCOS and controls (874.2 [SE 242
35 ion is common in patients with HIV/AIDS, and DHEA appears to be a useful treatment that is superior t
39 dy tested the hypothesis that serum DHEA and DHEA-S are predictors of major coronary heart disease (C
40 metry to analyze baseline levels of DHEA and DHEA-S in the prospective population-based Osteoporotic
44 duction of dehydroepiandrosterone (DHEA) and DHEA sulfate in the adrenal reticularis is inversely cor
46 creases in brain concentrations of DHEAS and DHEA after injection of DHEAS i.p. were attenuated by pr
47 9 +/- 0.1; peak: 12.7 +/- 0.9 microg/dL) and DHEA (baseline: 15.6 +/- 1.3; nadir: 11.2 +/- 1.0; peak:
50 onship between disease/fibrosis severity and DHEA-S levels was not seen in patients with cholestatic
52 ral conversion of the weak adrenal androgens DHEA and androstenedione into the AR ligands testosteron
57 DHEA/-S, evidence for an association between DHEA/-S levels and cardiovascular events is contradictor
58 trated a strong positive correlation between DHEA levels and performance on digit span forward/backwa
59 n disposition indexes did not differ between DHEA- and placebo-treated women, indicating that the sli
61 tudies have examined the interaction between DHEA- and testosterone-related cortical maturation in hu
63 or (S)-orteronel were identical for blocking DHEA formation from pregnenolone and for 17alpha-hydroxy
67 nt of primary rat hepatocytes decreased both DHEA- and nafenopin-induced FACO activity in primary rat
68 d sex steroid synthesis and disordered brain DHEA production and thus provide phenotypic clues about
69 ined the timescale of neuronal activation by DHEA, using light-induced release of DHEA from targeted
72 hat androgen precursors such as cholesterol, DHEA and progesterone, as well as androgens are highly u
79 ulin), hirsutism [ie, dehydroepiandosterone (DHEA) and androstenedione], and hunger (ie, ghrelin).
80 an increase in the dehydroepiandrostendione (DHEA) concentration and a reduction in the cortisol/DHEA
94 ect of administering dehydroepiandrosterone (DHEA) on visual-spatial performance in postmenopausal wo
96 gnenolone (PREG) and dehydroepiandrosterone (DHEA) have been reported to improve memory in aged roden
98 of osteoporosis, and dehydroepiandrosterone (DHEA), a ubiquitous steroid precusor, are reported to be
100 erone (T), 75 mg/day dehydroepiandrosterone (DHEA), or placebo (P); and 57 elderly women were studied
101 se reactions to form dehydroepiandrosterone (DHEA) and androstenedione (Andro), respectively, critica
102 ne and SULT2A1 gene, dehydroepiandrosterone (DHEA) and its sulfated form (DHEA-S), and characteristic
103 adrenal sex hormone dehydroepiandrosterone (DHEA), which is present in serum mainly as the sulfate D
104 To determine if dehydroepiandrosterone (DHEA) replacement improves insulin secretion, insulin ac
105 gen and neurosteroid dehydroepiandrosterone (DHEA) is available as over-the-counter hormonal therapy
106 hat the neurosteroid dehydroepiandrosterone (DHEA), when administered preclinically, could suppress p
107 t, the production of dehydroepiandrosterone (DHEA) and DHEA sulfate in the adrenal reticularis is inv
109 ministration of oral dehydroepiandrosterone (DHEA) during episodes of repeated hypoglycemia can preve
111 echnology to release dehydroepiandrosterone (DHEA), a neurosteroid that promotes neurogenesis and neu
112 reductions in serum dehydroepiandrosterone (DHEA) concentrations may be involved in bone mineral den
114 mutations underwent dehydroepiandrosterone (DHEA) challenge; serum androgens were measured every 30
118 mia were randomly assigned to receive either DHEA or placebo; 90% (69 of 77) of the DHEA patients and
119 docannabinoids, docosahexanoyl ethanolamide (DHEA) and eicosapentaenoyl ethanolamide (EPEA) by activa
120 ve oxygenated docosahexaenoyl ethanolamide- (DHEA) derived products that regulated leukocyte motility
121 ous infusion of DHEA-S (30 mg/kg; ANTE EUG + DHEA-S), 3) hyperinsulinemic hypoglycemia (2.8 +/- 0.1 m
122 E HYPO group versus the ANTE EUG, ANTE EUG + DHEA-S, and ANTE HYPO + DHEA-S groups (13 +/- 5 vs. 32 +
123 he ANTE HYPO versus the ANTE EUG, ANTE EUG + DHEA-S, and ANTE HYPO + DHEA-S groups (57 +/- 8 vs. 22 +
127 r Andro production from progesterone and for DHEA from pregnenolone, indicating a distributive charac
128 tor beta by CD4(+) T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct do
129 ein phosphatase 2A (PP2A) is responsible for DHEA action, and protein phosphatase 1 might be involved
131 piandrosterone (DHEA) and its sulfated form (DHEA-S), and characteristics of attention-deficit/hypera
136 n the ANTE HYPO group versus the ANTE HYPO + DHEA-S group (2.0 +/- 0.2 vs. 3.3 +/- 0.6 nmol/l; P < 0.
137 ANTE EUG, ANTE EUG + DHEA-S, and ANTE HYPO + DHEA-S groups (13 +/- 5 vs. 32 +/- 3, 38 +/- 7, and 29 +
138 ANTE EUG, ANTE EUG + DHEA-S, and ANTE HYPO + DHEA-S groups (57 +/- 8 vs. 22 +/- 5, 18 +/- 6, and 18 +
141 he purpose of this study was to determine if DHEA-S could preserve counterregulatory responses during
142 te-mediated cleavage of the 1,2-diol bond in DHEA produced multiresponsive core/shell microgels with
147 ted with a reduced risk (odds ratio per 1 ln[DHEA-S], 0.1; 95% confidence interval, 0.0-0.3; P = 0.00
148 cohorts in the advanced NAFLD group had low DHEA-S levels, with the majority in the hypoadrenal rang
149 ntal fibrosis stage was observed with a mean DHEA-S of 1.03 +/- 0.05, 0.96 +/- 0.07, 0.83 +/- 0.11, 0
152 s substantial change in the hormonal milieu, DHEA administration produced no beneficial effects on co
157 erature on vascular and metabolic actions of DHEA/-S, evidence for an association between DHEA/-S lev
159 We suggest that exogenous application of DHEA accelerates impaired wound repair, results which ma
161 suggest that physiological concentrations of DHEA activate a GPER intracellular signaling cascade tha
163 effects were mediated by local conversion of DHEA to estrogen, acting through the estrogen receptor,
164 f DHEA administration and the correlation of DHEA levels and performance in the placebo condition to
167 ential of our nanosensor in the detection of DHEA-S and other small molecules in biomedical applicati
168 free, specific and quantitative detection of DHEA-S at clinically appropriate concentrations with an
171 hodology that did not demonstrate effects of DHEA administration on episodic and short-term memory ta
172 ent demonstrated large beneficial effects of DHEA administration on Mental Rotation, Subject-Ordered
175 tion, coupled with the documented effects of DHEA's androgenic metabolites on visual-spatial performa
176 n vitro model to characterize the effects of DHEA, prolactin, 17beta-estradiol on insulin-growth fact
177 men with low levels of the sulfated form of DHEA and bioavailable testosterone and 57 elderly women
179 8) plus simultaneous intravenous infusion of DHEA-S (30 mg/kg; ANTE EUG + DHEA-S), 3) hyperinsulinemi
181 In addition, we show that local injection of DHEA accelerates impaired healing in an ageing mouse col
182 s spectrometry to analyze baseline levels of DHEA and DHEA-S in the prospective population-based Oste
183 ression analyses demonstrated that levels of DHEA and its metabolites were positively related to cogn
186 tion significantly increases serum levels of DHEA, DHEAS, testosterone and estrone and substantially
187 DHEA administration enhanced serum levels of DHEA, DHEAS, testosterone, and estrone, and regression a
188 and Visual Search tasks and serum levels of DHEA, DHEAS, testosterone, estrone, and cortisol were me
189 th advanced NAFLD had lower plasma levels of DHEA-S than patients with mild NAFLD in both the initial
190 2-16.4; P = 0.001), whereas higher levels of DHEA-S were associated with a reduced risk (odds ratio p
191 stances (P = 0.03), whereas higher levels of DHEA-S were associated with lower right atrial pressure
194 lation, patients were administered 400 mg of DHEA (N=14) or placebo (N=15) and underwent 3T fMRI whil
196 was significantly reduced after 6 months of DHEA therapy compared with placebo (-1119 muU/mL per 2 h
199 both sexes, and neither full replacement of DHEA (in elderly men and women) nor partial replacement
200 We conclude that 2 years of replacement of DHEA in elderly men and women does not improve insulin s
201 Although there have been multiple reports of DHEA's antidepressant and anxiolytic effects, no researc
202 ret the juxtaposition of the null results of DHEA administration and the correlation of DHEA levels a
205 essant medications.Intervention Six weeks of DHEA therapy, 90 mg/d for 3 weeks and 450 mg/d for 3 wee
209 effects of a four week regimen of 50 mg oral DHEA on performance on the digit span, verbal span, and
211 lled crossover design in which 50 mg of oral DHEA was administered daily in the drug condition to exp
217 and inhibitor studies suggest that the rapid DHEA-mediated increase in miR-21 involves a G-protein-co
221 in the placebo group, subjects who received DHEA for 2 years had an increase in plasma levels of sul
223 ese data provide novel evidence for relative DHEA-S deficiency in patients with histologically advanc
224 tabolism, 112 elderly subjects with relative DHEA deficiency ingested a labeled mixed meal and underw
225 females with subcutaneous pellets releasing DHEA or 17-OH pregnenolone at a constant rate failed to
228 cortical thickness associated with salivary DHEA and testosterone levels in a longitudinal sample of
230 This study tested the hypothesis that serum DHEA and DHEA-S are predictors of major coronary heart d
235 orter, Mrp4, transports the sulfated steroid DHEA-s, and sulfated bile acids interact with Mrp4 with
237 ch is present in serum mainly as the sulfate DHEA-S, is the most abundant steroid hormone in human bl
238 ly increased dehydroepiandrosterone sulfate (DHEA-S) and reduced estrone levels in KC patients compar
239 enal steroid dehydroepiandrosterone sulfate (DHEA-S) has been shown in several studies to oppose cort
240 vidence that dehydroepiandrosterone sulfate (DHEA-S) is involved in an organism's response to stress
241 osensor with dehydroepiandrosterone sulfate (DHEA-S), a small-molecule steroid hormone, as the target
243 estosterone, dehydroepiandrosterone sulfate [DHEA-S], and estradiol) influence cardiovascular disease
244 levels (E2, dehydroepiandrosterone-sulfate [DHEA-S], and testosterone) are associated with PAH in me
246 had an increase in plasma levels of sulfated DHEA by a median of 3.4 microg per milliliter (9.2 micro
250 n to relate baseline levels of testosterone, DHEA-S, and estradiol to the incidence of CVD (coronary,
251 aloxifene, which is considerably larger than DHEA, can bind only to the unliganded (open) enzyme, whe
257 s provide initial neuroimaging evidence that DHEA may be useful as a pharmacological intervention for
258 In the present study we hypothesized that DHEA may stimulate PI 3-kinase-dependent phosphorylation
265 on visual-spatial performance, suggests that DHEA administration may enhance visual-spatial performan
268 gnificant differences were noted between the DHEA and placebo groups for dry eye symptoms, objective
269 the response rate was 56% (43 of 77) for the DHEA group versus 31% (21 of 68) for the placebo group.
270 the response rate was 62% (43 of 69) for the DHEA group, compared to 33% (21 of 64) for the placebo p
278 ough 7 subjects met response criteria in the DHEA group, 5 met the criteria in the placebo group, and
279 +/- 0.7% after 2 y of supplementation in the DHEA group; however, in the placebo group, spine BMD was
280 ither DHEA or placebo; 90% (69 of 77) of the DHEA patients and 94% (64 of 68) of the placebo patients
281 ide prospective, empirical evidence that the DHEA-S level is increased by acute stress in healthy hum
282 acute stress in healthy humans and that the DHEA-S-cortisol ratio may index the degree to which an i
285 conversion of 17alpha-hydroxypregnenolone to DHEA than toward the 17alpha-hydroxylation of pregnenolo
286 an insulin sensitivity index in response to DHEA compared with placebo (+1.4 vs -0.7, P = .005).
287 stimulation of ET-1 secretion in response to DHEA may determine whether DHEA supplementation improves
288 omoter activity and secretion in response to DHEA treatment was augmented by PI 3-kinase blockade and
290 ients with SS should avoid using unregulated DHEA supplements, since long-term adverse consequences o
294 on in response to DHEA may determine whether DHEA supplementation improves or worsens cardiovascular
299 helial cells (BAEC and HAEC), treatment with DHEA (100 nM) acutely enhanced phosphorylation of FoxO1.
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。